Milliman and Akur8 Form Strategic Alliance to Bring Next Generation Pricing Capabilities to P&C Insurers, MGAs, and Start-Ups
9.11.2021 16:00:00 EET | Business Wire | Press release
Akur8, the next generation insurance pricing solution, and Milliman, a premier global consulting and actuarial firm, are pleased to announce a strategic alliance to empower property & casualty (non-life) insurance carriers, start-ups, and MGAs with next generation pricing capabilities. Together, this collaboration leapfrogs conventional ratemaking solutions to offer increased speed, accuracy, and governance in insurance pricing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211109005203/en/
Through its unique, cloud-based platform, Akur8 leverages an innovative combination of proprietary machine learning algorithms and Transparent AI™ to automate the insurance rate modelling process, while maintaining full transparency and interpretability of the models created. Akur8 offers end-to-end ratemaking capabilities to property and casualty (non-life) insurers, MGAs, and start-ups, while adhering to Actuarial Standards of Practice. This includes a feature that produces automated state filing documentation in all 50 U.S. states, easily enabling the model support to be filed with state regulators.
“Akur8 is a breakthrough innovation in the insurance pricing software landscape. They managed to automate the data-driven part of the pricing process while enabling actuaries and pricing teams to retain complete control over it,” says Sheri Scott, a principal and consulting actuary at Milliman.
With this alliance, Milliman’s actuarial and risk expertise is paired with Akur8’s revolutionary AI-driven pricing software to transform the ratemaking and pricing process for P&C insurers globally. By offering Akur8 in conjunction with Milliman’s expertise, national and multinational P&C carriers can expect a scalable solution that includes improved end-to-end pricing efficiency, expert pricing teams, faster time-to-market, greater modeling accuracy, improved internal governance and complete compliance.
“At Milliman, we understand the importance of bringing the best insurtech innovations to our clients in order to support them in their transformation journey,” says Richard Lord, Global Practice Director for property & casualty at Milliman. “This strategic alliance enables insurers, MGAs, and start-ups to benefit from world-class actuarial services and solutions along with cutting-edge operational technology.”
“Akur8 is delighted to team up with Milliman. The combination of Akur8’s state-of-the-art platform with Milliman’s leading actuarial expertise and data solutions creates a transformative insurtech solution that will leave conventional methods behind,” says Samuel Falmagne, CEO of Akur8.
About Akur8
Akur8 is the next generation insurance pricing solution. Akur8 is transforming insurance pricing with proprietary ML algorithms that automate rate making end-to-end, up until the generation of filing packages, while preserving control and transparency throughout the process and ensuring regulatory compliance. Akur8 is the only solution on the market reconciling Machine Learning and Actuarial worlds, empowering actuaries and pricing teams to make better decisions, faster.
About Milliman
Milliman is among the world’s largest providers of actuarial and related products and services. The firm has consulting practices in healthcare, property & casualty insurance, life insurance and financial services, and employee benefits. Founded in 1947, Milliman is an independent firm with offices in major cities around the globe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005203/en/
Contact information
Media
For Akur8
Anne-Laure Klein
anne-laure.klein@akur8-tech.com
+1 917-251-1593
For Milliman
Rebecca Driskill
rebecca.driskill@milliman.com
+1 646-473-3017
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom